Core Viewpoint - Southbound funds reduced their holdings in Fosun Pharma (02196.HK) by 12,500 shares on September 19, 2025, indicating a trend of net selling over the past 20 trading days [1] Group 1: Shareholding Changes - In the last 5 trading days, there were 3 days of net buying by southbound funds, totaling an increase of 744,400 shares [1] - Over the past 20 trading days, southbound funds have reduced their holdings on 15 days, with a total net reduction of 25,690,700 shares [1] - As of now, southbound funds hold 321 million shares of Fosun Pharma, accounting for 58.07% of the company's total issued ordinary shares [1] Group 2: Trading Data - On September 19, 2025, the total number of shares held was 321 million, with a change of -12,500 shares, reflecting a change of -0.00% [2] - On September 18, 2025, the total number of shares held was 321 million, with an increase of 1,714,000 shares, reflecting a change of 0.54% [2] - On September 17, 2025, the total number of shares held was 261 million, with a decrease of 4,086,000 shares, reflecting a change of -1.27% [2] Group 3: Company Overview - Fosun Pharma is primarily engaged in the research, manufacturing, and sales of pharmaceutical products, operating through five segments [2] - The pharmaceutical segment focuses on innovative drugs, mature pharmaceutical products, and vaccines [2] - The medical devices and diagnostics segment is involved in the manufacturing and sales of molecular diagnostics, immunodiagnostics, and microbiological diagnostic devices [2]

Group 1 - Juewei Foods faces risk warning and will be labeled as "ST Juewei" due to disclosure violations, with trading suspension on September 22, 2025 [2] - Fosun Pharma's subsidiary has received EU approval for its osteoporosis treatment products, with projected global sales of approximately $7.463 billion in 2024 [3] - Tailin Microelectronics has achieved mass production of its edge AI chips, with sales reaching millions of RMB in Q2 2025 [3] Group 2 - Saiseng Pharma's major shareholder plans to reduce their stake by up to 2% within three months [4] - Zhongcheng Group's stake in Zhongcheng Co. has increased to 42.12% after transferring shares to Zhongji Import and Export [5] - Dingsheng Co. plans to transfer 4.82% of its shares through an inquiry-based method [6] Group 3 - Fudan Fuhua will be labeled as "ST Fuhua" starting September 23, 2025, due to regulatory warnings [7] - Huadian Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange [8] - New Jufeng's shareholders plan to reduce their stake by up to 4.5% [9] Group 4 - Watson Bio's subsidiary has received acceptance for clinical trials of its mRNA vaccine for shingles [10] - Jintou Chengkai is adjusting its major asset restructuring plan, which will not change the controlling shareholder [11] - Hangdian Co. has seen a significant stock price increase of 46.52% over four trading days, raising concerns about potential volatility [12] Group 5 - Shenli Co. plans to reduce its stake by up to 3% due to funding needs [13] - Xinwangda's subsidiary is investing 60 million RMB to establish a private equity fund focused on energy storage projects [14] - Fuxai Technology has set an initial transfer price of 72.08 RMB per share for its inquiry-based transfer [15] Group 6 - Jilin Aodong's subsidiary has received a drug registration certificate for a traditional Chinese medicine [16] - Tianpu Co. has experienced a 13-day stock price surge, raising concerns about potential rapid declines [17] - Zhongchu Co. is increasing its investment in Zhongchu Hengke by 84.3146 million RMB through debt-to-equity swaps [18] Group 7 - Wuzhou Transportation's major shareholder has secured a loan commitment of up to 153 million RMB for share buybacks [19] - Shanxi Fenjiu has elected a new chairman and vice-chairmen for its board [20] - Qujiang Cultural Tourism has confirmed normal operations amid stock price fluctuations [21] Group 8 - Sike Rui will be labeled as "ST Sike Rui" and suspended for one day due to regulatory warnings [22] - Anning Co. is applying for a 3 billion RMB syndicated loan for asset restructuring [23] - Anning Co. has completed a significant debt restructuring plan totaling approximately 192.669 billion RMB [27] Group 9 - China Chemical reported a total contract amount of 256.339 billion RMB from January to August 2025 [28] - Jishi Media has elected a new chairman [29] - Lingyun Optics has adjusted its share repurchase price limit to 52 RMB per share [30] Group 10 - Baoli International plans to invest in semiconductor testing equipment company Hongtai Technology [29] - Pinming Technology's stock will continue to be suspended for up to three additional trading days [30] - Ankai Micro plans to invest 20 million RMB for a 4% stake in Shiqi Future [30]

（文章来源：证券日报） 本报讯天眼查App显示，近日，复星凯瑞（深圳）生物科技有限公司成立，法定代表人为陈星蓉，注册 资本1亿元，经营范围含医学研究和试验发展、工程和技术研究和试验发展、细胞技术研发和应用、人 体干细胞技术开发和应用、人体基因诊断与治疗技术开发、专用化学产品销售、仪器仪表销售等。股东 信息显示，该公司由复星医药旗下复星凯瑞（上海）生物科技有限公司全资持股。 ...

Group 1 - The core point of the news is that Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has received approval from the European Commission for the marketing authorization applications (MAAs) of two biosimilar products, BILDYOS® and BILPREVDA®, in the European Union and certain EEA countries [1][2] Group 2 - The biosimilar HLX14 is developed for the treatment of osteoporosis in postmenopausal women at high risk of fractures, along with other indications consistent with the reference drug label [2] - The product is expected to receive approval in the United States by August 2025 for eight indications related to osteoporosis treatment, covering all indications approved for the reference product in the U.S. [2] - As of July 2025, the cumulative R&D investment for HLX14 is approximately RMB 323 million (unaudited) [2]

Group 1 - The core point of the news is that Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has received approval from the European Commission for the marketing authorization applications (MAAs) of two biosimilar products, BILDYOS® and BILPREVDA®, in the European Union and certain EEA countries [1][2] Group 2 - The biosimilar HLX14 is developed for the treatment of osteoporosis in postmenopausal women at high risk of fractures, along with other indications consistent with the reference drug label [2] - The product is expected to receive approval in the United States by August 2025 for eight indications related to osteoporosis treatment, covering all indications approved for the reference product in the U.S. [2] - As of July 2025, the cumulative R&D investment for HLX14 is approximately RMB 323 million (unaudited) [2]

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 （股份代號：02196） 海外監管公告 证券代码：600196 股票简称：复星医药 编号：临 2025-149 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司藥品獲歐盟註冊批准的提示性公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年9 月1 9 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、潘東輝先生及吳以芳先生；本公司之獨立非執行董事為余梓山先生、王全弟先 ...

Group 1: Changshan Pharmaceutical - The company is preparing for clinical trials of Aibennate peptide for weight loss, with no current plans for oral formulation development [1] - Aibennate peptide is a long-acting GLP-1 receptor agonist, developed through chemical modification of exenatide [1] - The marketing preparation includes team building, product knowledge training, and marketing strategy formulation [1] Group 2: Fosun Pharma - Four innovative drugs approved in the first half of the year are expected to gradually increase sales in the coming months [2] - Innovative drug revenue exceeded 4.3 billion yuan, a year-on-year increase of 14.26%, accounting for over 30% of total drug revenue [2] - The company is actively participating in negotiations for the inclusion of its innovative drugs in insurance and national basic medical insurance directories [2] Group 3: Tiantan Biological Products - The company has established an international cooperation department to enhance its global market presence [3] - Products such as tetanus immunoglobulin and rabies immunoglobulin have already been exported [3] - The company is focused on international certification and registration of key products [3] Group 4: Kangtuo Medical - The US-based subsidiary BIOPLATE has launched a local production line for PEEK plates [4] - The company has completed market access in nearly 40 countries and regions [4] - The marketing of "4D bioactive plates" and PEEK fixation systems is underway in the US [4] Group 5: Tailong Pharmaceutical - The company is focusing on the development of modified new drugs across various therapeutic areas including respiratory, digestive, and oncology [5] - Projects in progress include treatments for Alzheimer's disease and schizophrenia [5] Group 6: Heng Rui Pharmaceutical - The HRS-5635 injection has been included in the list of proposed breakthrough therapies [6][7] - Chronic hepatitis B infection affects approximately 257 million people globally, with a significant mortality rate [7] - There is a pressing need for more effective treatments to achieve functional cure for chronic hepatitis B [7]

Core Viewpoint - Fosun Pharma's subsidiary Shanghai Fuhong Hanlin Biotech has received approval from the European Commission for the marketing authorization applications (MAAs) of two biosimilar products, BILDYOS® and BILPREVDA® [1] Group 1 - The approved products are both injections of dezhushe monoclonal antibody, with specifications of 60mg/mL for BILDYOS® and 120mg/1.7mL for BILPREVDA® [1] - The marketing authorization allows for the sale of these products in all EU member states as well as in Iceland, Liechtenstein, and Norway, which are part of the European Economic Area [1]

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., has received approval from the European Commission for the marketing authorization applications (MAAs) of two biosimilar products, BILDYOS® and BILPREVDA® [1] Group 1 - The approved products, BILDYOS® (60 mg/mL) and BILPREVDA® (120 mg/1.7 mL), are biosimilars of denosumab, intended for the treatment of osteoporosis in postmenopausal women at high risk of fractures [1] - The marketing authorization allows for the sale of these products in all EU member states as well as in Iceland, Liechtenstein, and Norway [1] - HLX14, the project code for these biosimilars, is developed independently by the group [1]

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., has received approval from the European Commission for the marketing authorization applications (MAAs) of two biosimilar products, BILDYOS® and BILPREVDA® [1] Group 1: Company Developments - The approved products, BILDYOS® (60 mg/mL) and BILPREVDA® (120 mg/1.7 mL), are biosimilars of denosumab, intended for the treatment of osteoporosis in postmenopausal women at high risk of fractures [1] - The marketing authorization allows for the sale of these products across all EU member states, as well as in Iceland, Liechtenstein, and Norway [1] Group 2: Industry Implications - The approval of HLX14 represents a significant advancement in the biosimilar market, particularly for osteoporosis treatments, which is a growing area of need in the healthcare sector [1]